image
Figure 2: Preliminary data showing that attenuation of reinstatement behaviour following intra-VTA administration of SB-334867 (3μg) is associated with differential expression of Fos-positive cells in reinstatementrelevant regions. As described previously (James et al., 2011), animals were tested for cue-induced reinstatement behaviour following intra-VTA administration of either SB-334867 (1 or 3μg) or vehicle. SB-334867 treatment dose-dependently attenuated reinstatement behaviour. Immediately following reinstatement testing, animals were transcardially perfused and brains were collected. Tissue from the PVT (Bregma -2.52 to -2.76), NACsh (2.04 to 2.28) and PF/LHA (-2.16 to -2.40) was then processed for immunohistochemical detection of Fos-protein (SB-334867 (3μg)- and vehicle -treated groups only, n=5-6). Intra-VTA administration of SB-334867 (3μg) was associated with a decrease in the number of Fos-positive cells within the PVT and an increase in numbers of Fos-positive cells in the NACsh (p’s < .05). No differences were observed between treatment groups in terms of numbers of Fos-positive cells in the PF/LHA (p>.05).
Goto home»